Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and evaluation of acute myelogenous leukemia (AML) begins with a thorough clinical assessment that integrates patient history, physical findings, and a series of targeted investigations. AML is an aggressive hematologic malignancy that accounts for approximately 30% of adult leukemias worldwide, and early recognition can dramatically improve therapeutic outcomes. This page is designed for international patients and healthcare professionals seeking a comprehensive overview of the diagnostic pathway at Liv Hospital, a JCI‑accredited center that offers coordinated, multilingual support throughout the process.
We will explore the step‑by‑step approach used by our multidisciplinary team, from initial symptom appraisal to advanced molecular profiling. Each section highlights the specific tests, imaging studies, and interpretive criteria that together form a robust evaluation framework, enabling personalized treatment planning for every patient.
The first encounter focuses on gathering detailed information about the patient’s recent health changes. A careful review of systems helps differentiate AML from other hematologic or infectious conditions.
Key symptoms commonly reported by patients with AML include:
Physical examination may reveal hepatosplenomegaly, lymphadenopathy, or petechiae. In the context of these findings, clinicians at Liv Hospital promptly order baseline laboratory studies to confirm suspicion and to guide further testing.
Laboratory evaluation forms the backbone of AML diagnosis. The following investigations are performed in a coordinated manner:
Essential blood tests include:
When blasts are identified, the laboratory team proceeds with flow cytometry to characterize surface antigens, providing early clues about lineage and guiding the selection of targeted agents.
While imaging is not diagnostic for AML per se, it plays a critical role in staging, assessing organ involvement, and identifying complications.
Common imaging modalities employed:
At Liv Hospital, imaging is coordinated with the hematology team to ensure that results are integrated into the overall diagnostic narrative, allowing for timely intervention when extramedullary disease is detected.
The definitive diagnosis of AML rests on bone marrow aspiration and biopsy. The procedure yields material for morphology, immunophenotyping, and genetic analysis.
Core components of bone marrow evaluation:
Below is a summary table of the most frequent cytogenetic abnormalities and their associated risk categories:
These cytogenetic insights are pivotal for risk stratification and directly influence the choice of induction and consolidation regimens.
Beyond conventional cytogenetics, next‑generation sequencing (NGS) panels have become standard for uncovering mutations that refine prognosis and open doors to targeted therapy.
Key molecular markers assessed include:
Liv Hospital’s molecular laboratory follows international quality standards, delivering results within 7‑10 days. The integration of molecular data with cytogenetics enables the application of the European LeukemiaNet (ELN) 2022 risk classification, guiding clinicians toward the most effective, individualized treatment pathways.
While AML does not follow a traditional TNM staging system, several prognostic scoring tools synthesize clinical and laboratory variables to predict outcomes.
Commonly used scoring systems:
These scores are calculated during the evaluation phase, allowing the multidisciplinary team at Liv Hospital to discuss realistic expectations with patients and to align therapeutic intensity with individual risk.
After completing the diagnostic work‑up, a case conference brings together hematologists, pathologists, radiologists, transplant specialists, and supportive‑care professionals. The goals are to:
Liv Hospital’s international patient services coordinate travel, interpreter assistance, and accommodation, ensuring that patients from abroad experience a seamless transition from diagnosis to treatment initiation.
Liv Hospital combines JCI accreditation, a dedicated oncology team, and a comprehensive international patient program. Our specialists follow evidence‑based protocols while tailoring each plan to the genetic profile of the leukemia. Patients benefit from state‑of‑the‑art laboratories, advanced imaging suites, and access to clinical trials that are not widely available. The hospital’s multilingual staff and 24‑hour concierge service simplify logistics, allowing patients to focus on recovery.
Ready to begin your personalized journey toward remission? Contact Liv Hospital’s international care team today to schedule a virtual consultation and learn how our expert diagnosis and evaluation process can pave the way for effective treatment.
Send us all your questions or requests, and our expert team will assist you.
Acute myelogenous leukemia often presents with nonspecific systemic symptoms. Patients frequently report unexplained fatigue or weakness due to anemia, and recurrent fevers or infections because of neutropenia. Easy bruising or spontaneous bleeding results from thrombocytopenia, while pallor and shortness of breath reflect low red‑cell counts. Bone or joint pain, especially in long bones, is caused by marrow expansion. Unintentional weight loss and loss of appetite are also common. Recognizing this constellation helps clinicians differentiate AML from other hematologic or infectious disorders.
The diagnostic work‑up starts with a complete blood count (CBC) that often shows anemia, thrombocytopenia, and circulating blasts. A peripheral blood smear confirms the presence and morphology of myeloblasts. A comprehensive metabolic panel assesses renal and hepatic function before therapy. Elevated lactate dehydrogenase (LDH) can indicate high tumor burden, while a coagulation profile detects disseminated intravascular coagulation, a serious AML complication. When blasts are identified, flow cytometry is performed to characterize surface antigens, providing early lineage information and guiding targeted treatment decisions.
The definitive AML diagnosis rests on bone marrow examination. Morphologic assessment confirms the presence of 20 % or more myeloblasts, meeting the WHO threshold. Flow cytometry immunophenotyping identifies lineage‑specific markers such as CD13, CD33, CD34, and CD117. Cytogenetic karyotyping detects chromosomal translocations, inversions, and deletions, while fluorescence in situ hybridization (FISH) targets recurrent lesions like t(8;21) or inv(16). These results are pivotal for risk stratification and directly influence the choice of induction and consolidation regimens.
The definitive AML diagnosis rests on bone marrow examination. Morphologic assessment confirms the presence of 20 % or more myeloblasts, meeting the WHO threshold. Flow cytometry immunophenotyping identifies lineage‑specific markers such as CD13, CD33, CD34, and CD117. Cytogenetic karyotyping detects chromosomal translocations, inversions, and deletions, while fluorescence in situ hybridization (FISH) targets recurrent lesions like t(8;21) or inv(16). These results are pivotal for risk stratification and directly influence the choice of induction and consolidation regimens.
Beyond conventional cytogenetics, next‑generation sequencing (NGS) detects mutations that further stratify AML risk. For example, FLT3‑ITD predicts a high relapse risk, while NPM1 mutation confers a favorable prognosis when FLT3‑ITD is absent. Biallelic CEBPA mutations are linked to improved survival, whereas TP53 mutations indicate an adverse outlook. IDH1/2 mutations are actionable with specific inhibitors. Liv Hospital’s molecular lab delivers results within 7‑10 days, allowing clinicians to apply the European LeukemiaNet (ELN) 2022 classification and select personalized, targeted therapies.
AML does not follow a traditional TNM staging system; instead, several prognostic tools are employed. The ELN Risk Classification integrates cytogenetic and molecular findings into favorable, intermediate, and adverse categories. For secondary AML, the IPSS‑R incorporates prior myelodysplastic syndrome features. The Weighted Leukemia Prognostic Index adds age, performance status, white‑blood‑cell count, and cytogenetics. These scores are calculated during the diagnostic phase, guiding discussions about therapeutic intensity and expected prognosis.
Liv Hospital’s international patient program is designed for patients traveling from abroad. The hospital provides multilingual staff to explain each step of the diagnostic work‑up, from symptom assessment to molecular testing. Dedicated coordinators arrange travel logistics, visa support, interpreter services, and comfortable accommodation near the facility. A 24‑hour concierge handles any urgent needs, allowing patients and families to focus on care rather than logistics. This comprehensive support ensures a seamless transition from diagnosis to treatment initiation.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
